Product Description
REGN5837, a bispecific antibody that clusters CD22-expressing tumor cells with CD28-expressing T cells, enhances odronextamab by potentiating T cell activation and cytolytic function. REGN5837 monotherapy shows limited activity and no toxicity in primate studies, it augments T cell activation when dosed in combination with odronextamab. (Sourced from: https://investor.regeneron.com/static-files/3f2c8835-1da3-43e6-a50d-7080d8d935ab)
Mechanisms of Action: CD22 Inhibitor,CD28 Inhibitor
Novel Mechanism: Yes
Modality: Bispecific Antibody
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Regeneron
Company Location: TARRYTOWN NY 10591
Company CEO: Leonard S. Schleifer
Additonal Commercial Interests: None
Clinical Description
![Map of Global Clinical Trials for REGN-5837](https://pryzm-maps.s3.us-west-2.amazonaws.com/9current_maps.png)
Countries in Clinic: United States
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Lymphoma, B-Cell|Lymphoma, Non-Hodgkin
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
ATHENA-1 | P1 |
Recruiting |
Lymphoma, B-Cell|Lymphoma, Non-Hodgkin |
2027-06-02 |